- Home
- ATHA
ATHA
Athira Pharma Inc.
as 07-26-2024 4:00pm EST
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 93.5M | IPO Year: | 2020 |
| Target Price: | $19.00 | AVG Volume (30 days): | 141.8K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $4.30 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Athira Pharma Inc. (ATHA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Romano Kelly A | ATHA | Director | Jun 21 '24 | Buy | $2.26 | 15,000 | $33,871.50 | 53,315 | SEC Form 4 |
| Romano Kelly A | ATHA | Director | Jun 21 '24 | Buy | $2.42 | 27,400 | $66,179.22 | 80,715 | SEC Form 4 |
| Litton Mark James | ATHA | CEO | Jan 4 '24 | Sell | $2.91 | 4,820 | $14,026.20 | 144,397 | SEC Form 4 |
| Worthington Mark | ATHA | GENERAL COUNSEL | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 34,452 | SEC Form 4 |
| CHURCH KEVIN | ATHA | CHIEF SCIENTIFIC OFFICER | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 80,256 | SEC Form 4 |
| Litton Mark James | ATHA | Chief Executive Officer | Jan 4 '24 | Sell | $2.91 | 4,820 | $14,026.20 | 144,397 | SEC Form 4 |
| Worthington Mark | ATHA | General Counsel | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 34,452 | SEC Form 4 |
| CHURCH KEVIN | ATHA | Chief Scientific Officer | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 80,256 | SEC Form 4 |
| Lenington Rachel | ATHA | COO AND CDO | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 13,395 | SEC Form 4 |
| Lenington Rachel | ATHA | Chief Operating Officer | Jan 4 '24 | Sell | $2.91 | 2,412 | $7,018.92 | 13,395 | SEC Form 4 |
| Gengos Andrew | ATHA | CFO AND CHIEF BUSINESS OFFICER | Jan 4 '24 | Sell | $2.91 | 1,208 | $3,515.28 | 83,804 | SEC Form 4 |
| Gengos Andrew | ATHA | See Below | Jan 4 '24 | Sell | $2.91 | 1,208 | $3,515.28 | 83,804 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ATHA | Director10% Owner | Dec 27 '23 | Buy | $2.28 | 32,134 | $73,265.52 | 4,829,412 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ATHA | Director10% Owner | Dec 27 '23 | Buy | $2.44 | 409,598 | $999,419.12 | 5,239,010 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ATHA | Director10% Owner | Dec 27 '23 | Buy | $2.38 | 163,954 | $390,210.52 | 5,402,964 | SEC Form 4 |
Latest Athira Pharma Inc. News
ATHA Breaking Stock News: Dive into ATHA Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
MT Newswires
17 days ago
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
GlobeNewswire
18 days ago
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Simply Wall St.
a month ago
retail investors who own 35% along with institutions invested in Athira Pharma, Inc. (NASDAQ:ATHA) saw increase in their holdings value last week
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 06/26/2024
GlobeNewswire
a month ago
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
GlobeNewswire
2 months ago
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Compare ATHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATHA Athira Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.